Oct 30, 2020 / Meeting Brief Medicare Advantage payment and access for enrollees with end-stage renal disease
Oct 30, 2020 / Meeting Brief Effects of pharmaceutical manufacturer rebates on Part D’s risk adjustment
Oct 29, 2020 / Comment Letters MedPAC comment on CMS’s proposed rule on Medicare Coverage of Innovative Technology and definition of ‘reasonable and necessary’ Research Areas: Beneficiaries and Coverage, Drugs, Devices, and Tests, Medicare Spending and Financing
Oct 06, 2020 / Transcripts October 2020 meeting transcript Research Areas: Delivery System Reforms, Drugs, Devices, and Tests, Hospitals, Physicians And Other Health Professionals, Post-Acute Care, Private Plans, Quality
Oct 02, 2020 / Presentations Vertical integration and Medicare payment policy Research Areas: Drugs, Devices, and Tests, Hospitals, Physicians And Other Health Professionals, Post-Acute Care, Private Plans
Oct 02, 2020 / Presentations The evolution of Medicare’s advanced alternative payment models Research Areas: Delivery System Reforms
Oct 02, 2020 / Comment Letters MedPAC comment on CMS’s proposed rule on the payment systems for hospital outpatient departments and ambulatory surgical centers for 2021 Research Areas: Ambulatory Care Settings, Drugs, Devices, and Tests, Hospitals, Medicare Spending and Financing
Oct 02, 2020 / Comment Letters MedPAC comment on CMS’s proposed rule on CY 2021 revisions to payment policies under the physician fee schedule and other changes to Part B payment policies Research Areas: Drugs, Devices, and Tests, Medicare Spending and Financing, Physicians And Other Health Professionals, Quality
Oct 01, 2020 / Presentations Balancing financial pressure and equity in Medicare Advantage benchmark policy Research Areas: Private Plans